Vamsidhar Velcheti MD FACP FCCP
Vamsidhar Velcheti MD FACP FCCP
Verified email at
Cited by
Cited by
Programmed death ligand-1 expression in non-small cell lung cancer
V Velcheti, KA Schalper, DE Carvajal, VK Anagnostou, KN Syrigos, ...
Laboratory investigation 94 (1), 107-116, 2014
Quantitative assessment of the heterogeneity of PD-L1 expression in non–small-cell lung cancer
J McLaughlin, G Han, KA Schalper, D Carvajal-Hausdorf, V Pelekanou, ...
JAMA oncology 2 (1), 46-54, 2016
In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas
KA Schalper, V Velcheti, D Carvajal, H Wimberly, J Brown, L Pusztai, ...
Clinical Cancer Research 20 (10), 2773-2782, 2014
PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer
H Wimberly, JR Brown, K Schalper, H Haack, MR Silver, C Nixon, ...
Cancer immunology research 3 (4), 326-332, 2015
Objective measurement and clinical significance of TILs in non–small cell lung cancer
KA Schalper, J Brown, D Carvajal-Hausdorf, J McLaughlin, V Velcheti, ...
Journal of the National Cancer Institute 107 (3), dju435, 2015
Incidence of pneumonitis with use of PD-1 and PD-L1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials.
M Khunger, V Pasupuleti, S Rakshit, P Jain, PJ Mazzone, J Stevenson, ...
Journal of Clinical Oncology 35 (15_suppl), e20647-e20647, 2017
Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3
J Wang, MF Sanmamed, I Datar, TT Su, L Ji, J Sun, L Chen, Y Chen, ...
Cell 176 (1-2), 334-347. e12, 2019
Radiomics and radiogenomics in lung cancer: a review for the clinician
R Thawani, M McLane, N Beig, S Ghose, P Prasanna, V Velcheti, ...
Lung cancer 115, 34-41, 2018
Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry
O Gautschi, J Milia, T Filleron, J Wolf, DP Carbone, D Owen, R Camidge, ...
Journal of Clinical Oncology 35 (13), 1403, 2017
Artificial intelligence in digital pathology—new tools for diagnosis and precision oncology
K Bera, KA Schalper, DL Rimm, V Velcheti, A Madabhushi
Nature reviews Clinical oncology 16 (11), 703-715, 2019
Selective RET kinase inhibition for patients with RET-altered cancers
V Subbiah, V Velcheti, BB Tuch, K Ebata, NL Busaidy, ME Cabanillas, ...
Annals of Oncology 29 (8), 1869-1876, 2018
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
JM Wrangle, V Velcheti, MR Patel, E Garrett-Mayer, EG Hill, JG Ravenel, ...
The Lancet Oncology 19 (5), 694-704, 2018
Immunotherapy in non–small cell lung cancer: facts and hopes
DB Doroshow, MF Sanmamed, K Hastings, K Politi, DL Rimm, L Chen, ...
Clinical Cancer Research 25 (15), 4592-4602, 2019
Interleukin-8 in cancer pathogenesis, treatment and follow-up
C Alfaro, MF Sanmamed, ME Rodríguez-Ruiz, Á Teijeira, C Oñate, ...
Cancer treatment reviews 60, 24-31, 2017
Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity
C Calabrese, E Kirchner, A Kontzias, V Velcheti, LH Calabrese
RMD open 3 (1), e000412, 2017
Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer
JA Rehman, G Han, DE Carvajal-Hausdorf, BE Wasserman, V Pelekanou, ...
Modern Pathology 30 (3), 340-349, 2017
Evaluation of PD-L1 expression and associated tumor-infiltrating lymphocytes in laryngeal squamous cell carcinoma
M Vassilakopoulou, M Avgeris, V Velcheti, V Kotoula, T Rampias, ...
Clinical Cancer Research 22 (3), 704-713, 2016
Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1)
V Velcheti, DL Rimm, KA Schalper
Journal of thoracic oncology 8 (6), 803-805, 2013
Differential expression and significance of PD-L1, IDO-1, and B7-H4 in human lung cancer
KA Schalper, D Carvajal-Hausdorf, J McLaughlin, M Altan, V Velcheti, ...
Clinical Cancer Research 23 (2), 370-378, 2017
A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.
AE Drilon, V Subbiah, GR Oxnard, TM Bauer, V Velcheti, NJ Lakhani, ...
Journal of Clinical Oncology 36 (15_suppl), 102-102, 2018
The system can't perform the operation now. Try again later.
Articles 1–20